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A B S T R A C T
Purpose
Data from clinical trials are used for drug registration; however, many cancer medicines are ultimately
used off-label. This study examines the extent to which the clinical practice use of trastuzumab for the
treatment of metastatic breast cancer differs from its use under trial conditions.
Methods
This study involved all women (N  1,469) with metastatic breast cancer who received
trastuzumab in Australia between December 2001 and March 2005. Given that Australia operates
a universal health care system, administrative databases could be examined to determine the
duration of therapy, rate of off-label use, compliance with cardiac monitoring, and the extent of
drug wastage (volume and cost).
Results
A total of 433 enrollees (29.5%) received trastuzumab as monotherapy and 1,036 enrollees
(70.5%) received the drug in combination with chemotherapy. A total of 321 women (22%)
received off-label trastuzumab. The median duration of trastuzumab therapy was longer than that
on trial: 5.6 v 3.1 months for enrollees receiving monotherapy and 12.5 v 6.9 months for
concomitant chemotherapy. Only 47 (3%) of enrollees received cardiac monitoring before and
during trastuzumab therapy. We estimated 24% of trastuzumab dispensed was discarded, at a
cost of $21.1 million Australian. Alternative administration schedules and the addition of another
vial size potentially reduce wastage to 6% of volume dispensed.
Conclusion
Debates about the use of expensive cancer medicines should consider postmarketing assess-
ments as well as trial experience. The longer duration of trastuzumab use in clinical practice and
the high rates of off-label use provide incentive for new clinical trials. Strategies to improve cardiac
monitoring and to minimize drug wastage are issues that require immediate attention.
J Clin Oncol 25:3688-3693. © 2007 by American Society of Clinical Oncology
INTRODUCTION
Much of what we know about the benefits and tox-
icities of drug treatments are based on phase III
clinical trials, conducted in highly select populations
receiving exceptionally good care. The pressure to
subsidize drugs that potentially improve the length
of life and/or quality of life is intense. Consequently,
more drugs are approved for marketing on the basis
of interim data, before benefits and risks have been
quantified fully.1 Data derived from the real-world
setting may be the only opportunity to study the
benefits and risks associated with new drugs and
estimate the extent of off-label use in large numbers
of typical patients. However, postmarketing obser-
vational studies are not routine in most countries. In
a recent debate about the increasing costs of cancer
care, experts called for the evidence base for new
treatments to be improved for the purpose of im-
proving patient management and informing re-
source allocation decisions.2-4
Increasing health care costs must be considered
from the perspective of the payer. In the United
States, individuals or private health providers fre-
quently subsidize drug costs. In contrast, Australia,
like most of Europe, operates a universal health sys-
tem involving public and private sectors. Under sin-
gle user–pay systems, individual wealth or health
insurance status does not influence access to
taxpayer-funded drugs or medical services. Not un-
expectedly, cost-effectiveness analysis is used fre-
quently to assist government payers to make
decisions about whether a new therapy should be
made available to the population. Given that the
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Australian government bears the cost of health care, it has compre-
hensive data, based on payment, for the services and drugs pro-
vided to its citizens.
The recombinant antibody trastuzumab (Herceptin, Genentech,
South San Francisco, CA) exemplifies the new generation of targeted
anticancer therapies. Trastuzumab inhibits the growth of breast can-
cer cells by binding to human epidermal growth factor receptor 2
(HER-2). Overexpression of this receptor is found in approximately
25% of breast cancers and occurs as a consequence of amplification of
theHER2/neu gene.5,6 Clinical trials demonstrated trastuzumab, used
alone7 or in combination with chemotherapy,8 slowed the progression
of HER-2–positive metastatic breast cancer. In patients failing prior
chemotherapy for metastatic breast cancer, trastuzumab used as a
single agent reduced tumor size in 15% of patients.7 In individuals not
receiving prior chemotherapy, the combination of cytotoxics and
trastuzumab delayed time to metastatic disease progression by about 3
months.8 More recently, studies have shown that trastuzumab pre-
vents disease recurrence, at least in the short term, in women with
early-stage breast cancer.9-12 In comparison with chemotherapy, tras-
tuzumab is well tolerated and has few acute adverse effects. However,
retrospective analysis of trial data and single institutional case re-
views13,14 have shown trastuzumab causes cardiac failure, particularly
when administered concurrently with anthracyclines.15 In contrast to
metastatic breast cancer studies, trastuzumab trials in early breast
cancer have excluded individuals with preexisting heart disease and
incorporated compulsory cardiac monitoring in their design.9-12
Despite the clinical efficacy of trastuzumab, the price of this drug
places it beyond the reach of most individuals (approximately $55,000
Australian dollars [AUD] for a 70-kg patient for 1 year of treatment).
Not surprisingly, regulatory approval of trastuzumab was closely fol-
lowed by campaigns lobbying for public subsidy. In Australia, trastu-
zumab was not considered cost effective for the treatment of
metastatic breast cancer, and was not approved for listing on the
Pharmaceutical Benefits Schedule, Australia’s list of government-
subsidized medicines. Under intense pressure, the federal government
took the unprecedented decision of creating a taxpayer-funded Her-
ceptin Program entirely outside the Pharmaceutical Benefits Scheme
(PBS). Since December 2001, the Herceptin Program has provided
free trastuzumab access to treat HER-2–positive metastatic breast
cancer. To emulate trastuzumab use in the pivotal clinical trials7,8 and
to ensure drug use complied with registered indications, a number of
restrictions to trastuzumab access were imposed by Medicare Austra-
lia, the Herceptin Program administering body (Table 1).16
In this study, we use Australian national health administrative
databases to examine trastuzumab use for the treatment of metastatic
breast cancer. Specifically, we determine the duration of trastuzumab
therapy, extent of off-label use, extent to which patients undergo
cardiac monitoring, and wastage (volume and cost) associated with
trastuzumab administration schedules and the discarding of unused
vial portions. Finally, these findings are compared with the usage
patterns reported in the key clinical trials.
METHODS
Data Sources and Extraction
This study was approved by the St Vincent’s and Mater Health, Sydney
Human Research Ethics Committee, and the Medicare Australia External
Request Evaluation Committee. Three Medicare Australia databases (Table 2)
were supplied to evaluate the Herceptin Program between December 2001 and
March 2005. To protect patient confidentiality, Medicare Australia staff ex-
tracted data from the program database and allocated a unique scrambled
identifier to the records of each enrollee. These same identifiers were then
assigned to enrollees’ PBS and Medicare Benefits Scheme (MBS) records. All
three databases were supplied to the investigators, stripped of name and
address identifiers, and subsequently linked to enable person-level data anal-
ysis. SAS software, version 8 (SAS Institute Inc, Cary, NC) was used for
statistical analyses.
Duration of Trastuzumab Therapy
Duration of trastuzumab therapy was calculated as the period from the
first trastuzumab dispensing date to the last dispensing date plus an additional
30 days (it is standard practice under the program to dispense trastuzumab as
a 1-month supply). A period of more than 90 days between trastuzumab
dispensing records was considered a separate period of exposure. Program and
PBS dispensing records were used to classify enrollees according to whether
their first period of trastuzumab exposure (hereafter referred to as the first
course of therapy) was administered as monotherapy or as concomitant chem-
otherapy. Enrollees were included in the concomitant chemotherapy group if
they were identified in the program database as receiving trastuzumab with
taxanes, or were identified in the program database as receiving monotherapy
but had evidence of at least two PBS chemotherapy dispensing records (Ap-
pendix Table A1, online only) more than 7 days apart during their first course
of trastuzumab therapy. All remaining enrollees were included in the mono-
therapy group. Off-label trastuzumab use was determined by identifying co-
hort members administered trastuzumab outside its registered indications for
use (Table 1). For example, patients with off-label use were those registered in
the program as receiving trastuzumab as monotherapy with at least two PBS
dispensing records for taxane or nontaxane chemotherapy, or those registered
to receive trastuzumab with taxanes who had at least two PBS dispensing
records for second-line nontaxane chemotherapy.
Table 1. Eligibility for Herceptin in Australia16
Under the Herceptin Program, trastuzumab is available free to Australian patients
With HER-2–positive metastatic breast cancer either in combination with taxanes for patients who have not received chemotherapy for metastatic disease
As monotherapy for the treatment of those patients who have received one or more chemotherapy regimen(s) for metastatic disease
Patients must
Have IHC evidence of HER-2 protein at the 3 level, or
Have IHC evidence of HER-2 protein at the 2 level, subsequently confirmed as exhibiting HER2 gene amplification by FISH, or
Exhibit HER2 amplification by FISH
NOTE. Prescribers must register the patient with Medicare Australia for participation in the Herceptin Program and confirm patient registration every 6 months. To
register, the prescriber must provide evidence that the patient is eligible (via faxed pathology reports and verbal confirmation), evidence of patient and prescriber
consent, and patient details including patient weight (as dosage is based on weight).
Abbreviations: HER-2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; FISH, fluorescent in situ hybridization.
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The median duration of trastuzumab therapy (excluding gaps in therapy
of more than 90 days) was estimated for enrollees with a minimum program
follow-up period equivalent to the pivotal trials (15 months for monotherapy7
and 31 months for concomitant chemotherapy8). Kaplan-Meier survival
methodology also was used to estimate the duration of the first course of
trastuzumab therapy based on data from the entire program cohort, irrespec-
tive of follow-up time.
Cardiac Monitoring
The number of echocardiography (MBS item code 55113 corresponding
to International Classification of Diseases, 10th revision, code 55112) and/or
multiple gated acquisition (MUGA) scans (MBS and International Classifica-
tion of Diseases, 10th revision, code 61313) occurring 30 days before the first
course of trastuzumab therapy and at any time during the first course of
therapy was determined. The relationship between cardiac monitoring and
anthracycline use (defined as one or more PBS anthracycline dispensing
records preceding or occurring at any time during the first course of trastu-
zumab therapy) was also assessed.
MBS items are for tests subsidized by the federal government. Program
enrollees may also have had echocardiography and MUGA scans performed as
inpatients in state-funded hospitals (these procedures are not captured in the
MBS data). In the absence of unit record data on program enrollees from
state-based data sources, aggregated data from the MBS online statistics17 and
National Hospital Morbidity Data procedures database18 were used to esti-
mate the extent to which echocardiography and MUGA scans are captured in
hospital data collections compared with MBS data. For the purposes of the
analysis the National Hospital Morbidity Data, data were restricted to separa-
tions for tests performed on day-only admissions, given that the majority of
oncology patients are in this category. Between July 2000 and June 2006, 99%
of MUGA scans and echocardiograms recorded in the two databases were
captured in the MBS database.
Trastuzumab Wastage
Trastuzumab is packaged in one 150-mL vial (concentration, 1 mg/mL)
and dosing is calculated according to patient weight. In Australia, it is man-
dated that when only a portion of a vial is required for a patient, the unused
balance must be discarded.19 Program enrollees received trastuzumab as a 4
mg/kg loading dose and 2 mg/kg standard weekly dose. The volume of trastu-
zumab dispensed (in liters) and discarded during the study period, and asso-
ciated expenditure based on a vial cost of AUD$1,031.2120, was calculated.
Volume calculations assumed one dispensing record equated to 1 month of
therapy, a 90-day break in therapy was a separate course of therapy (requiring
a loading dose at the beginning of the next course), and patient weight re-
mained constant throughout the treatment period. Sensitivity analyses were
conducted to assess the impact of a 3-week dosing schedule (8 mg/kg loading
dose and 6 mg/kg standard dose once every 3 weeks) and of the availability of
additional vial sizes (150 plus 100 mL or 150 plus 200 mL).
RESULTS
Between December 2001 and March 2005, 1,469 women with HER-
2–positive metastatic breast cancer were enrolled onto the Herceptin
Program. The average age of the cohort was 54.3 years (range, 22 to 95
years); 7% (n 103) of enrollees were between 75 to 84 years old and
1.3% (n 19) were age 85 years. The average weight of the cohort
was 69.9 kg (range, 29 to 150 kg) and 74% of women were 50 to 75 kg.
Eighty-eight percent (n  1,291) of enrollees had HER-2–positive
breast cancer as demonstrated by 3 immunohistochemistry, 3.8%
(n  56) demonstrated by fluorescent in situ hybridization (FISH)
gene amplification, and 8.3% (n 122) demonstrated by 2 immu-
nohistochemistry and confirmatory FISH testing.
Herceptin Program records indicated 662 enrollees (45.1%) re-
ceived trastuzumab as monotherapy and 807 enrollees (54.9%) re-
ceived the drug in combination with taxanes. On the basis of program
and PBS records, 1,036 (70.5%) enrollees received concomitant
Table 2. Characteristics of the Medicare Australia Data Sources
Database Description Period Data Extracted Data Capture
Herceptin Program Program participants December 2001-March 2005 Year of birth, state of residence,
postal code, patient weight at
program commencement,
treatment qualification, type
of therapy†, trastuzumab-
dispensing dates
All individuals qualifying for
trastuzumab therapy on the
Herceptin Program
PBS Medicines dispensed January 2001-March 2005 PBS pharmaceutical item code,
drug name, strength,
anatomical therapeutic
chemical classification, date
of supply, number of
prescriptions supplied and
repeats
Data recorded from
prescriptions for which the
pharmaceutical item cost is
greater than the patient
contribution (at the general
or concessional rate);
medicines dispensed to
public hospital inpatients are
not captured
MBS Medical services billed January 2001-March 2005 Date of service and MBS item
code
Services that qualify for
Medicare benefits, such as
doctor visits, pathology, and
diagnostic testing; only
claims information is
collected so diagnostic and
clinical information is not
available; services provided
to public hospital inpatients
and public hospital
emergency departments are
not captured
Abbreviations: PBS, Pharmaceutical Benefits Scheme; MBS, Medicare Benefits Scheme; IHC, immunohistochemistry; FISH, fluorescent in situ hybridization.
IHC 3, IHC 2, and confirmed by FISH, or FISH only.
†Trastuzumab as monotherapy or trastuzumab with taxanes.
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chemotherapy at some time during their first course of trastu-
zumab therapy. Of these individuals, 761 received taxanes alone,
192 received taxanes and nontaxane chemotherapy, and 83 were
treated with nontaxane chemotherapy alone. Of program enrollees
receiving other chemotherapy, 213 received vinorelbine and 33
received anthracyclines (Table 3); 321 women (22%) received off-
label trastuzumab (Table 4).
Duration of Therapy
For program enrollees who had a minimum follow-up period
equivalent to that of the pivotal clinical trials, the median duration of
trastuzumab therapy was 4.9 months (range, 1.0 to 40.2 months) for
monotherapy, and 11.6 months (range, 1.0 to 41.3 months) for enroll-
ees receiving trastuzumab with chemotherapy (Table 5). A total of 96
enrollees had a break in treatment of more than 90 days and at least
one additional period of exposure to trastuzumab therapy. When the
additional exposure periods were incorporated in the estimates, dura-
tion of therapy increased to 5.9 months (range, 1.0 to 40.2 months) for
monotherapy, and 12.7 months (range, 1.0 to 41.3 months) for enroll-
ees receiving trastuzumab with chemotherapy. For the entire program
cohort, the estimated median duration of the first course of trastu-
zumab therapy (based on Kaplan-Meier methodology) was 5.6
months (range, 1.0 to 40.2 months) for enrollees receiving trastu-
zumab as monotherapy and 12.5 months (range, 1.0 to 41.3 months)
for enrollees receiving trastuzumab with concomitant chemotherapy
(Table 5). Thus, the duration of therapy in clinical practice was longer
than that observed in the pivotal trials (Table 5).
Cardiac Monitoring
A total of 158 (10.8%) women received cardiac monitoring up to
30 days before the commencement of the first course of trastuzumab
therapy, 378 women (25.7%) were monitored at some time during the
first course of therapy, and 47 women (3.2%) were monitored before
and during their first course of therapy. Anthracycline use, before or
during trastuzumab therapy, did not influence the frequency of car-
diac monitoring.
Trastuzumab Wastage
During the 40-month period, an estimated 87,102 trastuzumab
vials were dispensed (costing AUD$88.9 million) and 3,100 L or the
equivalent of 20,667 vials of unused trastuzumab were discarded
(costing AUD$21.1 million). Thus, 24% of all trastuzumab dispensed
during the period was discarded. On the basis of dosing once every 3
weeks rather than a weekly dosing schedule, 13% of total volume
would have been discarded (11,014 L dispensed; 1,383 L discarded),
accompanied by an AUD$18.3 million reduction in cost. On the
basis of dosing once every 3 weeks and the availability of the
existing 150-mL vial and a 100- or 200-mL vial, wastage would
have been reduced to 5% of total volume dispensed (9,669 L
dispensed and 508 L discarded).
DISCUSSION
In this study, health administrative databases were used to examine,
for the first time to our knowledge, trastuzumab use for the treatment
of metastatic breast cancer outside trial conditions. We highlight the
way that real-word clinical practice deviates from trial conditions and
the limitations of using clinical trial outcomes as the sole source of
evidence to inform resource allocation decisions. The cost effective-
ness of trastuzumab in the treatment of metastatic breast cancer is
determined, in part, by the duration and cost of therapy per patient.
Our study suggests the duration of trastuzumab treatment in clinical
practice is longer than that observed under trial conditions (Table 5).
In drawing this conclusion, we relied on the fact that time to progres-
sion, as reported in the pivotal clinical trials, was a close estimate for
treatment duration (Roche Products Pty Ltd, New South Wales, Aus-
tralia, personal communication, January 2007). The longer duration
of therapy in clinical practice may reflect a greater benefit of trastu-
zumab, perhaps because of better HER-2 target identification (Table
5), or the concomitant use of more effective (albeit off-label) nontax-
ane chemotherapies.21 An alternative explanation may be that the
longer treatment durations simply reflect a reluctance on the part of
physicians and patients to cease a drug viewed as doing no harm.22
According to this viewpoint, disease progression while patients are
receiving trastuzumab therapy may be addressed by changing the
chemotherapy regimen without ceasing trastuzumab. This proposi-
tion is supported by our finding that a significant number of enrollees
received additional or alternative chemotherapy treatments (mainly
vinorelbine) at some stage during trastuzumab therapy. This occurred
even though trastuzumab is only registered for use with taxanes.
Although extended therapy and the addition of new chemotherapy
partners may be beneficial, this treatment strategy should be evaluated
in well-designed clinical trials.
Our study also illustrates the potential financial savings associ-
ated with more appropriate diagnostic tests for HER-2 status or alter-
native vial sizes. Selection for trastuzumab therapy relies on the
accurate determination of HER-2 status, which is currently best
Table 3. Number of Herceptin Program Enrollees Receiving Chemotherapy
During Their First Course of Trastuzumab With and Without Taxanes
Chemotherapy
Taxanes With Other
Chemotherapy
(n  192)
Other Chemotherapy
Without Taxanes
(n  83)
Anthracyclines 23 10
Platinum compounds 44 12
Thiotepa 0 0
Methotrexate 3 2
Vinblastine 0 0
Vinorelbine 146 67
Etoposide 0 1
Other chemotherapy was administered at some stage during trastuzumab
therapy, but not necessarily at the same time as the taxanes.
Table 4. Trastuzumab Use According to Herceptin Program Records
(registered indication) and Actual Use (validation with PBS records)
Therapy
Herceptin Program Records
Monotherapy
(n  662)
With Taxanes
(n  807)
Monotherapy 433 Nil
With taxanes alone 94 667
With taxanes and nontaxane chemotherapy 52 140 (92)
With nontaxane chemotherapy alone 83 Nil
Abbreviation: PBS, Pharmaceutical Benefits Scheme.
Off-label use.
Herceptin and Breast Cancer
www.jco.org 3691
Downloaded from ascopubs.org by University of Queensland on January 22, 2017 from 130.102.082.101
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
performed using assays detectingHER2gene amplification (for exam-
ple by FISH).23 In contrast, 70% to 80% of breast cancers assessed as
2 by immunohistochemistry and 16% to 30% of cancers assessed as
3 by this technique do not have HER2 amplification.24-26 Nearly
90% of women accessing the Herceptin Program had 3 tumor
immunostaining, and Australian data suggest 20% of these are false-
positive results.24 Therefore, it is likely that up to 270 program enroll-
ees did not gain a benefit from trastuzumab therapy because their
tumor was not HER-2 positive. Conversely, some patients, inevitably,
did not qualify for Herceptin Program treatment because of false-
negative immunostaining results.26 The inaccurate identification of
the HER-2 target, whether in a trial setting or clinical practice, may
result in inappropriate and wasteful use of this expensive therapy.
Additional sources of trastuzumab wastage relate to its supply in
a single vial size and weekly administration schedules. During the first
40 months of the Herceptin Program, nearly one fourth of trastu-
zumab dispensed was discarded, at an estimated cost of AUD$21.1
million. Nearly 4 years after the program started, dosing schedules
once every 3 weeks were approved—a change that potentially reduces
wastage by half. Repackaging to provide an additional vial size could
reduce wastage further to less than 6% of total volume dispensed and
thus improve the cost effectiveness of trastuzumab. Although some
drug wastage is inevitable, it is also clear that altering vial sizes and
administration schedules are simple cost-containment measures that
can be implemented without adversely affecting patient outcomes.
An alarming study finding was the low rate of cardiac monitor-
ing. Only 3% of enrollees underwent echocardiography or MUGA
scans before or during trastuzumab therapy. Women with previous or
concomitant anthracycline therapy were no more likely to receive
cardiac monitoring than were women in other groups. A most dis-
turbing finding was that 33 program enrollees received at least two
cycles of concomitant anthracyclines despite compelling evidence that
this places them at significant risk for cardiotoxicity.8,13,15 Trastu-
zumab currently is available for the treatment of early-stage breast
cancer and the pressure to use this drug is intense.27 Given our find-
ings on the extent of cardiac monitoring in the metastatic setting, it is
conceivable and of concern that women with early-stage breast cancer
may also fail to receive adequate monitoring.
Our study has several limitations. The data sources used were
established for the reimbursement of items billed under three federally
funded community programs and contain no clinical data. However,
secondary health data sources have been used routinely and are con-
sidered a valid and reliable means of evaluating the impact of pharma-
ceutical interventions.28 This study was limited further by the inability
to link the national data sources to state and territory collections such
as hospitals admissions, procedures performed on hospital inpatients,
and the death register. For this reason, our analysis may have under-
estimated the use of investigative procedures. However, given that
most Australian oncology practice occurs in the community setting,
the magnitude of these underestimations is likely to be small.
There is little doubt that many Australians with metastatic HER-
2–positive breast cancer benefited from trastuzumab treatment; how-
ever, it is clear that this expensive drug has not always been prescribed
appropriately. Enormous pressure is placed on regulatory bodies
Table 5. Herceptin Program Versus the Pivotal Phase II and III Trastuzumab Trials
Characteristic
Herceptin Program Clinical Trials
Single-Agent
Trastuzumab
Trastuzumab 
Chemotherapy
Phase II Single-Agent
Trastuzumab7
Phase III Trastuzumab 
Chemotherapy Arms8
Trastuzumab
 AC
Trastuzumab
 Paclitaxel
No. of patients 433 1,036 222 143 92
Age, years
Mean 56 53 54 54 51
Range 22-95 26-92 28-86 27-76 25-77
HER-2 assessment
2 on IHC 50 35 24
3 on IHC 377 914 172 108 68
FISH 56 122
Duration of therapy, months
First course, minimum follow-up period
equivalent to trials
Median 4.9† 11.6‡
Range 1.0-40.2 1.0-41.3
Kaplan-Meier analysis
Median 5.6 12.5
Range 1.0-40.2 1.0-41.3
Inferred from time to progression
Median 3.1§ 7.8§ 6.9§
Range 0.0-28.0
Abbreviations: HER-2, human epidermal growth factor receptor 2; AC, anthracycline and cyclophosphamide; IHC, immunohistochemistry; FISH, fluorescent in
situ hybridization.
Concomitant chemotherapy.
†n  273.
‡  291.
§Time to progression observed in the studies is a reasonable and close estimate to the treatment duration (Roche Products Pty Ltd, New South Wales, Australia,
personal communication, December 2006).
Range not reported in article.
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worldwide to use fast-track drug approval before the full extent of
benefits and risks are evaluated. Given these pressures, and those
placed on public and private health insurers to make the drugs
affordable to individuals, it is imperative that outcomes of obser-
vational studies complement trial evidence, inform the design of
additional clinical trials, and inform clinical practice and policy
decision making.
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